Herpes Simplex Virus (HSV-2) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.
Vaccine manufacturers have pursued the development of both prophylactic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term pharmacotherapy. Ideally the vaccine would also reduce transmission (shedding) so having a wider public health benefit. A number of Phase II HSV TX programs operated by Genocea (GEN-003), Agenus (HerpV) and COR-1 (Admedus) have already shown in a clinical setting that a HSV TX vaccine is feasible.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of a HSV therapeutic vaccine across the major Western markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing/penetration estimates and revenues per competitor. LO/BASE/HI target product profile (TPP) scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included on latest trends in disease epidemiology/dynamics and the competitive landscape.